DF/HCC Renal Cancer SPORE

DF/HCC 肾癌孢子

基本信息

项目摘要

DESCRIPTION (provided by applicant): This application represents the creation of a Specialized Program of Research Excellence in Renal Cancer originating from the Renal Cancer Program-in-Development of the newly configured Dana-Farber Harvard Cancer Center (DF/HCC) and the Beth Israel Deaconess Medical Center. The DF/HCC Renal Cancer SPORE includes investigators from all the Harvard affiliated hospitals - the Beth Israel Deaconess Medical Center, the Dana-Farber Cancer Institute, the Massachusetts General Hospital, the Brigham and Women's Hospital, and the Children's Hospital Medical Center, as well as the Harvard School of Public Health. Five major projects are supported through this application including: 1) Identification of markers for early detection and monitoring of high-risk RCC populations; 2) Inhibition of VHL-regulated growth factor pathways for treatment of RCC; 3) Combination radiofrequency ablation and antivascular/anitangiogenesis therapy for RCC; 4) Identification of molecular and immunologic correlates of RCC prognosis and responsiveness to therapy, and 5) Dendritic cell/tumor fusions in conjunction with IL-12 as novel immunotherapy for RCC. These projects are integrated by four cores. These are: 1) Administration, Evaluation and Planning; 2) Biostatistics; 3) Tissue Acquisition, Pathology and Clinical Data, and 4) Monitoring. This SPORE application outlines a Developmental Projects Program which includes a plan for selection and review of projects, and eight sample projects that could be considered for support. We also include a Career Development Award Program which outlines a mechanism for the identification, support, and review of talented young investigators in renal cancer. The overall goal of the DF/HCC Renal Cancer SPORE is the translation of biological and technological advances into clinically meaningful advances for patients with renal cancer.
描述(由申请人提供):本申请代表一项肾癌卓越研究专业计划的创建,该计划源于新配置的Dana-Farber哈佛癌症中心(DF/HCC)和贝斯以色列女执事医疗中心的肾癌发展计划。 DF/HCC肾癌SPORE包括来自所有哈佛附属医院的研究人员-贝斯以色列女执事医疗中心,达纳-法伯癌症研究所,马萨诸塞州总医院,布里格姆妇女医院和儿童医院医疗中心,以及哈佛公共卫生学院。 通过该应用程序支持五个主要项目,包括:1)识别用于早期检测和监测高危RCC人群的标志物; 2)抑制VHL调节的生长因子通路用于治疗RCC; 3)联合射频消融和抗血管/抗血管生成治疗RCC; 4)RCC预后和对治疗的反应性的分子和免疫学相关性的鉴定,和5)树突状细胞/肿瘤融合与IL-12结合作为RCC的新免疫疗法。 这些项目由四个核心组成。它们是:1)管理、评价和规划; 2)生物统计学; 3)组织采集、病理学和临床数据;以及4)监测。 此SPORE应用程序概述了开发项目计划,其中包括项目选择和审查计划,以及可以考虑支持的八个示例项目。 我们还包括一个职业发展奖励计划,该计划概述了一种识别,支持和审查有才华的肾癌年轻研究人员的机制。DF/HCC肾癌SPORE的总体目标是将生物学和技术进步转化为对肾癌患者有临床意义的进步。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michael Benjamin Atkins其他文献

Michael Benjamin Atkins的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michael Benjamin Atkins', 18)}}的其他基金

(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors
(PQ
  • 批准号:
    10462570
  • 财政年份:
    2018
  • 资助金额:
    $ 245.83万
  • 项目类别:
(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors
(PQ
  • 批准号:
    10001451
  • 财政年份:
    2018
  • 资助金额:
    $ 245.83万
  • 项目类别:
Career Development Program
职业发展计划
  • 批准号:
    7742551
  • 财政年份:
    2009
  • 资助金额:
    $ 245.83万
  • 项目类别:
Developmental Research Program
发展研究计划
  • 批准号:
    7742550
  • 财政年份:
    2009
  • 资助金额:
    $ 245.83万
  • 项目类别:
DF/HCC Renal Cancer SPORE
DF/HCC 肾癌孢子
  • 批准号:
    7276728
  • 财政年份:
    2003
  • 资助金额:
    $ 245.83万
  • 项目类别:
DF/HCC Renal Cancer SPORE
DF/HCC 肾癌孢子
  • 批准号:
    6671085
  • 财政年份:
    2003
  • 资助金额:
    $ 245.83万
  • 项目类别:
DF/HCC Renal Cancer SPORE
DF/HCC 肾癌孢子
  • 批准号:
    6801547
  • 财政年份:
    2003
  • 资助金额:
    $ 245.83万
  • 项目类别:
DF/HCC Kidney Cancer SPORE
DF/HCC 肾癌孢子
  • 批准号:
    7910615
  • 财政年份:
    2003
  • 资助金额:
    $ 245.83万
  • 项目类别:
DF/HCC Kidney Cancer SPORE
DF/HCC 肾癌孢子
  • 批准号:
    7691537
  • 财政年份:
    2003
  • 资助金额:
    $ 245.83万
  • 项目类别:
DF/HCC Renal Cancer SPORE
DF/HCC 肾癌孢子
  • 批准号:
    7099645
  • 财政年份:
    2003
  • 资助金额:
    $ 245.83万
  • 项目类别:

相似海外基金

Combination therapy for renal cell carcinoma using oncolytic virus G47d
使用溶瘤病毒 G47d 联合治疗肾细胞癌
  • 批准号:
    23K08752
  • 财政年份:
    2023
  • 资助金额:
    $ 245.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Sensitization to RIPK1-dependent death as a strategy to enhance response of renal cell carcinoma (RCC) to immunotherapy
对 RIPK1 依赖性死亡的敏感性作为增强肾细胞癌 (RCC) 对免疫治疗反应的策略
  • 批准号:
    10721156
  • 财政年份:
    2023
  • 资助金额:
    $ 245.83万
  • 项目类别:
Association between efficacy of Immuno-Oncology combination therapy for renal cell carcinoma and gut microbiota including fungi and viruses
肾细胞癌免疫肿瘤联合疗法的疗效与肠道微生物群(包括真菌和病毒)之间的关联
  • 批准号:
    23K08749
  • 财政年份:
    2023
  • 资助金额:
    $ 245.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Investigating the Role of KEAP1 Germline and Somatic Mutations in Renal Cell Carcinoma
研究 KEAP1 种系和体细胞突变在肾细胞癌中的作用
  • 批准号:
    10740481
  • 财政年份:
    2023
  • 资助金额:
    $ 245.83万
  • 项目类别:
The role of the RNA demethylase FTO in metabolic reprogramming of renal cell carcinoma
RNA去甲基化酶FTO在肾细胞癌代谢重编程中的作用
  • 批准号:
    10659085
  • 财政年份:
    2023
  • 资助金额:
    $ 245.83万
  • 项目类别:
Synthetic Lethal Targeting of SETD2 in Renal Cell Carcinoma
SETD2 在肾细胞癌中的合成致死靶向
  • 批准号:
    10607320
  • 财政年份:
    2023
  • 资助金额:
    $ 245.83万
  • 项目类别:
Targeting PRMT1 in Clear Cell Renal Cell Carcinoma
透明细胞肾细胞癌中的靶向 PRMT1
  • 批准号:
    488615
  • 财政年份:
    2023
  • 资助金额:
    $ 245.83万
  • 项目类别:
    Operating Grants
Molecular mechanisms and therapeutic targeting of activated NRF2 signaling in MiT/TFE translocation renal cell carcinoma
MiT/TFE 易位肾细胞癌中激活的 NRF2 信号传导的分子机制和治疗靶向
  • 批准号:
    10633699
  • 财政年份:
    2023
  • 资助金额:
    $ 245.83万
  • 项目类别:
Elucidating the Understudied Kinase PNCK as a Prospective Drug Target in Renal Cell Carcinoma
阐明正在研究的激酶 PNCK 作为肾细胞癌的潜在药物靶点
  • 批准号:
    10667043
  • 财政年份:
    2023
  • 资助金额:
    $ 245.83万
  • 项目类别:
Pro-tumorigenic roles of a VHL isoform in Clear Cell Renal Cell Carcinoma
VHL 亚型在透明细胞肾细胞癌中的促肿瘤作用
  • 批准号:
    10649049
  • 财政年份:
    2023
  • 资助金额:
    $ 245.83万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了